KEY STORY
-
Bharat Biotech has released the results from the phase 3 clinical trials of Covaxin after evaluation of 130 confirmed cases. Covaxin’s demonstrated an overall efficacy of 77.8% against symptomatic COVID-19 and 65.2% against the Delta Plus variant.
-
The vaccine also showed to be 93.4% effective against severe symptomatic Covid-19, the company claimed. “Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic COVID19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant,” Bharat Biotech said.
-
Further, the safety results showed no cases of anaphylaxis or vaccine-related deaths were reported among those who took Covaxin. The company said that the vaccine was well tolerated with minimal adverse events after immunisation.
-
“No cases of anaphylaxis or vaccine-related deaths were reported. Interpretation: BBV152 was immunogenic and highly efficacious against symptomatic and asymptomatic COVID 19 variant associated disease, particularly against severe disease in adults,” it said.
Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic COVID19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant: Bharat Biotech
— ANI (@ANI) July 3, 2021
